James Halley

There are plenty of healthcare stocks that have seen share growth this year. Here are three lesser-known stocks that have the potential to continue that growth this month and beyond.

The states are the two largest markets about to open to adult-use marijuana.

Gaming platform Roblox filed for its IPO recently. The company has made huge gains in users during the pandemic.

Sotera Health, Maravai Life Sciences, and Olema Pharmaceuticals all have an Initial Public Offering with the NASDAQ this month. Are these healthcare companies worth getting excited about?

Oregon just decriminalized the use of the psychedelic compound psilocybin. Could Compass Pathways, which is testing a synthetic form of the drug as a mental health therapy, be on the cusp of something big?

These two companies are battling for market share of continuous glucose monitoring devices for diabetes, with each coming out with new models soon.

Now that a COVID-19 vaccine may be on the way, which telehealth company is best positioned for continued growth?

Biogen's Alzheimer's disease drug, aducanumab, got positive news from the FDA last week. If the drug is approved, what does that mean for other companies with prospective Alzheimer's drug candidates?

Vaxart isn't making a profit yet, but it has paid investors handsomely this year after climbing 1,360% year to date.

One of these two cannabis companies is a much better long-term investment.

These companies haven't been fully recognized by the market, but are sure-fire revenue (and dividend) deliverers.

These three medical insurance stocks all trade for 14 times earnings or less, and they pay dividends.

These three investments provide dividends of at least 4%, along with growth potential and a safe payout ratio.

COVID-19 has heightened the demand for companies that specialize in infection control.

"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.

Co-Diagnostics has had a wild run this year. Is it too late to get in on this booming biotech stock?

Chasing these three high-yield dividend stocks could ultimately be hazardous to your portfolio.

Shares have risen more than 62% year to date. Is the medical device company still a good buy?

Curaleaf stock is already up more than 41% this year, but three main factors could give the Massachusetts company an even bigger boost.

Gilead's stock has been volatile, but if you had bought it early, right after its IPO in 1992, you would have done quite well.